1 KYTHERA Biopharmaceuticals Analyst Ratings, Earnings, Dividends and Insider Trades | $KYTH | NASDAQ:KYTH | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact KYTHERA Biopharmaceuticals Company Profile (NASDAQ:KYTH) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for KYTHERA Biopharmaceuticals (NASDAQ:KYTH) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s), 6 Buy Rating(s)Consensus Rating:Buy (Score: 2.86)Consensus Price Target: $45.33 (0.70% upside) Analysts' Ratings History for KYTHERA Biopharmaceuticals (NASDAQ:KYTH) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare10/30/2013FBR & Co.Initiated CoverageOutperformView 10/30/2013FBR Capital MarketsInitiated CoverageOutperform$58.00View 10/25/2013Bank of AmericaInitiated CoverageBuyView 9/17/2013JPMorgan Chase & Co.Boost Price TargetOverweight$34.00 -> $45.00View 9/17/2013Cowen and CompanyReiterated RatingBuy$50.00View 9/17/2013Leerink SwannBoost Price Target$34.00 -> $50.00View 9/17/2013Goldman SachsInitiated CoverageNeutral$37.00View 9/6/2013Cowen and CompanyInitiated CoverageOutperform$50.00View 8/7/2013Leerink SwannBoost Price Target$28.00 -> $34.00View 8/7/2013JPMorgan Chase & Co.Boost Price Target$30.00 -> $34.00View 5/14/2013Lazard Ltd.Lower Price TargetBuy$33.00 -> $32.00View 5/4/2013Ativo ResearchInitiated CoverageMost UnfavorableView 11/5/2012JPMorgan Chase & Co.Initiated CoverageOverweightView 11/5/2012Lazard Ltd.Initiated CoverageBuyView 11/5/2012Leerink SwannInitiated CoverageOutperform$28.00View 11/5/2012Goldman SachsInitiated CoverageNeutral$23.00View (Data available from 3/7/2012 forward) Earnings History for KYTHERA Biopharmaceuticals (NASDAQ:KYTH)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare11/14/2013Q313($0.72)($0.62)ViewN/AView 8/6/2013Q2 2013($0.70)($0.67)ViewN/AView 5/13/2013Q1 2013($0.97)($0.77)ViewN/AView 3/21/2013Q4 2012($0.76)($1.04)ViewN/AView 11/13/2012Q312$0.00($11.41)ViewN/AView (Data available from 1/1/2011 forward) Dividend History for KYTHERA Biopharmaceuticals (NASDAQ:KYTH)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for KYTHERA Biopharmaceuticals (NASDAQ:KYTH)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare3/3/2014Jeffrey WebsterVPSell4,000$49.55$198,200.00View 3/3/2014Nathaniel DavidDirectorSell5,099$49.18$250,768.82View 2/20/2014John SmitherCFOSell2,250$49.75$111,937.50View 2/14/2014John SmitherCFOSell1,125$50.00$56,250.00View 2/3/2014Jeffrey WebsterVPSell4,000$45.40$181,600.00View 2/3/2014Keith LeonardCEOSell12,740$45.35$577,759.00View 2/3/2014Nathaniel DavidDirectorSell5,000$45.31$226,550.00View 1/21/2014John SmitherCFOSell1,125$42.54$47,857.50View 1/2/2014Jeffrey WebsterVPSell4,000$37.38$149,520.00View 1/2/2014Keith LeonardCEOSell12,480$37.38$466,502.40View 12/2/2013Jeffrey WebsterVPSell4,000$38.69$154,760.00View 12/2/2013Keith LeonardCEOSell12,220$38.95$475,969.00View 12/2/2013Nathaniel DavidDirectorSell4,800$38.72$185,856.00View 11/1/2013Jeffrey D WebsterVPSell4,000$44.90$179,600.00View 11/1/2013Keith R LeonardCEOSell11,960$44.22$528,871.20View 11/1/2013Nathaniel E DavidDirectorSell4,698$43.93$206,383.14View 9/16/2013Keith LeonardCEOSell2,860$33.62$96,153.20View 9/10/2013John W SmitherCFOSell40,000$30.02$1,200,800.00View 9/10/2013Keith KleinGeneral CounselSell4,500$32.00$144,000.00View 9/10/2013Nathaniel E DavidDirectorSell6,376$31.00$197,656.00View 9/3/2013Jeffrey WebsterVPSell4,000$26.11$104,440.00View 9/3/2013Keith LeonardCEOSell8,580$26.12$224,109.60View 9/3/2013Nathaniel DavidDirectorSell3,375$26.12$88,155.00View 8/1/2013Jeffrey D WebsterVPSell4,000$26.76$107,040.00View 8/1/2013John W SmitherCFOSell10,000$26.80$268,000.00View 8/1/2013Keith R LeonardCEOSell8,385$26.73$224,131.05View 8/1/2013Nathaniel E DavidDirectorSell3,301$26.76$88,334.76View 7/15/2013Keith R LeonardCEOSell1,365$28.90$39,448.50View 7/1/2013Jeffrey D WebsterVPSell4,000$27.06$108,240.00View 7/1/2013Keith R LeonardCEOSell8,190$27.10$221,949.00View 7/1/2013Nathaniel E DavidDirectorSell3,225$27.07$87,300.75View 6/28/2013Keith KleinGeneral CounselSell4,500$27.00$121,500.00View 6/17/2013John W SmitherCFOSell6,000$26.00$156,000.00View 6/17/2013Keith R LeonardCEOSell1,332$25.69$34,219.08View 6/17/2013Nathaniel E DavidDirectorSell1,538$26.00$39,988.00View 6/7/2013Jeffrey D WebsterVPSell4,000$25.00$100,000.00View 6/3/2013Keith R LeonardCEOSell6,663$21.25$141,588.75View 5/31/2013Jeffrey D WebsterVPSell4,000$22.26$89,040.00View 5/1/2013Nathaniel E DavidDirectorSell2,625$21.42$56,227.50View (Data available from 1/1/2013 forward) About KYTHERA Biopharmaceuticals KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate, ATX-101, is a injectable drug in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted, ATX-101 has exhibited results in the reduction of submental fat. ATX-101 contains a synthetic form of sodium deoxycholate. In the United States and Canada, the Company is conducting two pivotal Phase III trials of ATX-101 for the reduction of submental fat. The Company initiated this pivotal Phase III clinical program, with planned enrollment of 1,000 patients, in March 2012. Headlines: (2/28) KYTHERA Biopharmaceuticals to Present at Cowen and Company 34th Annual Health Care Conference Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: KYTH CUSIP: 50157010 Key Metrics: Previous Close: $43.3650 Day Moving Average: $47.6076200 Day Moving Average: $41.0227 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $963.4MCurrent Quarter EPS Consensus Estimate: $-2.74 EPS Additional Links: View KYTH on Google FinanceView KYTH on Yahoo FinanceView KYTH's Company Profile on ReutersSearch for KYTHERA Biopharmaceuticals Inc. on Google KYTHERA Biopharmaceuticals (NASDAQ:KYTH) Chart for Friday, March, 7, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.